Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01294774 | Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus | PHASE2 | COMPLETED | 10 | — | — | Feb 1, 2011 | Oct 1, 2012 | Mar 22, 2017 | 8 | Germany, Greece +1 |
| Arm | Type | Description |
|---|---|---|
| KRP203 - 1.2 mg | EXPERIMENTAL | - |
| Placebo to KRP203 - 1.2 mg | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| KRP203 - 1.2mg | DRUG | - |
| Placebo to KRP203 - 1.2 mg | DRUG | - |
Inclusion Criteria: * Male and female patients,18 to 65 years of age inclusive, who have been defined as having SCLE based on the typical clinical picture and the characteristic histopathological features as described by Sontheimer et al. at least three months before study entry (screening) Exclus...